Q&A: New Rules for Clinical Trials conducted in the EU
Recommendation

16-18 June 2026
Management, Supply and Quality Assurance of Clinical Trials
Following the positive vote in Parliament for the new Clinical Trial Regulation, the EU Commission has published a set of Q&As on clinical trials.
Here it is also discussed why the current legislation is being replaced and the main changes are summarised:
- The new authorisation procedure
- The simplified reporting procedures
- More rights for the Commission to conduct controls
In the new regulation, the concept of tacit agreement in the assessment phase of an application will be extended. According to the Q&A, this was needed "to avoid bottlenecks and delays in the procedure".
Related GMP News
03.06.2026In-use Storage Time of Reconstituted Medicines
28.05.2026New EMA Q&A on the Implementation of 3DP Technology
28.05.2026EMA publishes Presentations on Contractual Agreements in Clinical Trials
28.05.2026UK Substantial Modifications Pilot
07.05.2026What are the GMP Requirements for Investigational Medicinal Products (IMPs)?


